Structure base drug discovery company
Amura Holdings Ltd., Minerva Building, Babraham Research Campus, Babraham, CB22 3AT, U.K.
Home
Company
Board of Directors
Senior Management
Company Information
Licensing
Disclaimer
Technologies
Programmes
News
Contact
Sitemap
Search
 
 
     
 

Company Profile

Amura is a structure-based drug discovery business specialising in diseases such as osteoporosis, osteoarthritis, bone metastasis, autoimmunity, chronic pain and malaria. Amura has a proprietary technology platform (AMcore) that provides a turnkey solution for the discovery of small-molecule inhibitors against cysteine peptidases (e.g. cathepsin enzymes); which are commercially attractive therapeutic targets.  Amura compounds possess highly desirable drug-like properties; thereby facilitating the rapid and innovative discovery of orally active pharmaceutical ingredients across several disease areas.  Amura has assembled advanced pre-clinical packages for its programmes demonstrating efficacy in disease-related animal models as well as safety pharmacology profiling.  Amura intends to license  out the programmes.  Amuras research and development activities are based at the Babraham Research Campus, Cambridge, United Kingdom.

Amura has licensing opportunities for its core business based around the AMcore technology.  Amura also has licensing opportunities for its anti-bacterials programme based on -lactamase inhibitors.

 

 

 
     
Email: amura@amura.co.uk
Phone: +44(0)1223 839797 Fax: +44(0)1223 839898 Copyright 2009 Amura Holdings Ltd.